HP Ingredients' ParActin granted product license from Health Canada for support of joint health

Alissa Marrapodi

Alissa Marrapodi is Industry Insights Contributor, Custom Content Editor, MJH Life Sciences.

ParActin Andrographis paniculata from HP Ingredients, was granted a product license (#80109555) from Health Canada to support joint health symptoms.

ParActin Andrographis paniculata from HP Ingredients (Bradenton, FL), was granted a product license (#80109555) from Health Canada. The Natural and Non-prescription Health Products Directorate (NNHPD) concluded that HP Ingredients’ application for ParActin is in compliance pursuant to section 7 of the Natural Health Products Regulations (NHPR), specifically, that one 150-mg capsule twice daily “Helps to relieve joint health associated with osteoarthritis of the knee.”

“Canadian consumers will now be able to purchase ParActin-containing supplements clearly for joint health, and can be comfortable discussing usage with their osteopaths, general practitioners and naturopaths,” said Annie Eng, CEO, HP Ingredients, in a press release. “Health Canada is sometimes looked at as the ‘gold standard’ when reviewing claims, because two double-blind placebo-controlled, peer-reviewed published human studies are required to make the claim,” Eng emphasized. “Health Canada licensure also provides our U.S. customers that are marketing ParActin in the United States, and around the world, confidence when making DSHEA-compliant structure function claims.”